Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen (review of TA255)

Kearns, B; Pandor, A; Stevenson, M; Sanderson, J; Chambers, D; Clowes, M; Kumar, M.S and Graham, J; Benjamin  Kearns; Abdullah Pandor; Matt  Stevenson; Jean Sanderson; Duncan Chambers; Mark Clowes; Satish Kumar; John Graham

Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen (review of TA255)

Kearns, B; Pandor, A; Stevenson, M; Sanderson, J; Chambers, D; Clowes, M; Kumar, M.S and Graham, J, Benjamin Kearns, Abdullah Pandor, Matt Stevenson, Jean Sanderson, Duncan Chambers, Mark Clowes, Satish Kumar, John Graham

Research output: Book/Report › Commissioned report

791 Downloads (Pure)

Abstract

Prostate cancer is the most common cancer amongst men in the England and currently affects ~40,000 people around 6,000 of whom suffer from metastatic disease. Overall patients with metastatic disease have a life expectancy of less than 24 months and a poor prognosis.

Docetaxel was the first agent to show survival benefit in metastatic Hormone Refractory Prostate Cancer (mHRPC) and since approval by NICE in 2006 (TA101) has for many years been the mainstay of treatment.

To appraise the clinical and cost effectiveness of cabazitaxel within its marketing authorisation for treating hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Original language	English
Place of Publication	National Institute for Health and Care Excellence
Publisher	National Institute for Health and Care Excellence
Number of pages	36
Publication status	Published - 01 Jun 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen (review of TA255)
© 2016 National Institute for Health and Care Excellence
Final published version, 4.72 MBLicence: Unspecified

https://www.nice.org.uk/guidance/TA391/documents/committee-papers

M. Satish Kumar
- s.kumar@qub.ac.uk
- School of Natural and Built Environment - Senior Lecturer
- Culture and Society
Person: Academic

Cite this

Kearns, B; Pandor, A; Stevenson, M; Sanderson, J; Chambers, D; Clowes, M; Kumar, M.S and Graham, J, Kearns, B., Pandor, A., Stevenson, M., Sanderson, J., Chambers, D., Clowes, M., Kumar, S., & Graham, J. (2016). Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen (review of TA255). National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/TA391/documents/committee-papers

Kearns, B; Pandor, A; Stevenson, M; Sanderson, J; Chambers, D; Clowes, M; Kumar, M.S and Graham, J ; Kearns, Benjamin ; Pandor, Abdullah ; Stevenson, Matt ; Sanderson, Jean ; Chambers, Duncan ; Clowes, Mark ; Kumar, Satish ; Graham, John. / Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen (review of TA255). National Institute for Health and Care Excellence : National Institute for Health and Care Excellence, 2016. 36 p.

@book{92af720c4a15470ea1a348940736fe4f,

title = "Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen (review of TA255)",

abstract = "Prostate cancer is the most common cancer amongst men in the England and currently affects ~40,000 people around 6,000 of whom suffer from metastatic disease. Overall patients with metastatic disease have a life expectancy of less than 24 months and a poor prognosis.Docetaxel was the first agent to show survival benefit in metastatic Hormone Refractory Prostate Cancer (mHRPC) and since approval by NICE in 2006 (TA101) has for many years been the mainstay of treatment.To appraise the clinical and cost effectiveness of cabazitaxel within its marketing authorisation for treating hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen.",

author = "Kumar, {Mathummal Satish} and {Kearns, B; Pandor, A; Stevenson, M; Sanderson, J; Chambers, D; Clowes, M; Kumar, M.S and Graham, J} and Benjamin Kearns and Abdullah Pandor and Matt Stevenson and Jean Sanderson and Duncan Chambers and Mark Clowes and Satish Kumar and John Graham",

year = "2016",

month = jun,

day = "1",

language = "English",

publisher = "National Institute for Health and Care Excellence",

}

Kearns, B; Pandor, A; Stevenson, M; Sanderson, J; Chambers, D; Clowes, M; Kumar, M.S and Graham, J, Kearns, B, Pandor, A, Stevenson, M, Sanderson, J, Chambers, D, Clowes, M, Kumar, S & Graham, J 2016, Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen (review of TA255). National Institute for Health and Care Excellence, National Institute for Health and Care Excellence. <https://www.nice.org.uk/guidance/TA391/documents/committee-papers>

Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen (review of TA255). / Kearns, B; Pandor, A; Stevenson, M; Sanderson, J; Chambers, D; Clowes, M; Kumar, M.S and Graham, J; Kearns, Benjamin ; Pandor, Abdullah; Stevenson, Matt ; Sanderson, Jean; Chambers, Duncan; Clowes, Mark; Kumar, Satish; Graham, John.

National Institute for Health and Care Excellence : National Institute for Health and Care Excellence, 2016. 36 p.

Research output: Book/Report › Commissioned report

TY - BOOK

T1 - Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen (review of TA255)

AU - Kumar, Mathummal Satish

AU - Kearns, B; Pandor, A; Stevenson, M; Sanderson, J; Chambers, D; Clowes, M; Kumar, M.S and Graham, J

AU - Kearns, Benjamin

AU - Pandor, Abdullah

AU - Stevenson, Matt

AU - Sanderson, Jean

AU - Chambers, Duncan

AU - Clowes, Mark

AU - Kumar, Satish

AU - Graham, John

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Prostate cancer is the most common cancer amongst men in the England and currently affects ~40,000 people around 6,000 of whom suffer from metastatic disease. Overall patients with metastatic disease have a life expectancy of less than 24 months and a poor prognosis.Docetaxel was the first agent to show survival benefit in metastatic Hormone Refractory Prostate Cancer (mHRPC) and since approval by NICE in 2006 (TA101) has for many years been the mainstay of treatment.To appraise the clinical and cost effectiveness of cabazitaxel within its marketing authorisation for treating hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen.

AB - Prostate cancer is the most common cancer amongst men in the England and currently affects ~40,000 people around 6,000 of whom suffer from metastatic disease. Overall patients with metastatic disease have a life expectancy of less than 24 months and a poor prognosis.Docetaxel was the first agent to show survival benefit in metastatic Hormone Refractory Prostate Cancer (mHRPC) and since approval by NICE in 2006 (TA101) has for many years been the mainstay of treatment.To appraise the clinical and cost effectiveness of cabazitaxel within its marketing authorisation for treating hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen.

M3 - Commissioned report

BT - Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen (review of TA255)

PB - National Institute for Health and Care Excellence

CY - National Institute for Health and Care Excellence

ER -

Kearns, B; Pandor, A; Stevenson, M; Sanderson, J; Chambers, D; Clowes, M; Kumar, M.S and Graham, J, Kearns B, Pandor A, Stevenson M, Sanderson J, Chambers D et al. Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen (review of TA255). National Institute for Health and Care Excellence: National Institute for Health and Care Excellence, 2016. 36 p.

Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen (review of TA255)

Abstract

UN SDGs

Access to Document

Fingerprint

Profiles

M. Satish Kumar

Cite this